Debiopharm Debio 1143-SCCHN-301
A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
©2019 Fort Wayne Medical Oncology and Hematology. All Rights Reserved.